FluoretiQ
FluoretiQ Ltd, founded in 2017, is dedicated to developing fast, accurate point-of-care diagnostics to improve antibiotic stewardship and combat antimicrobial resistance (AMR). Their innovative technology platforms, NANOPLEX® and SCFI™, enable rapid bacterial identification and antibiotic susceptibility testing, supporting evidence-based treatments and reducing misuse of antibiotics. The company collaborates with various partners and has a strong leadership team focused on transforming infection management.
Industries
Nr. of Employees
small (1-50)
Products
VERI-5 (research use only desktop instrument and single‑use cartridges)
Compact desktop instrument with single‑use cartridge system designed to detect bacteriuria rapidly at the point of care; released as a research‑use only product.
VERI-5 (research use only desktop instrument and single‑use cartridges)
Compact desktop instrument with single‑use cartridge system designed to detect bacteriuria rapidly at the point of care; released as a research‑use only product.
Services
Licensing of diagnostic technologies and collaborative R&D partnerships with academic and industry partners for application development and commercialisation.
Collaborative projects with academic groups and grant‑funded programmes to develop, validate and translate diagnostics from concept to prototype.
Licensing of diagnostic technologies and collaborative R&D partnerships with academic and industry partners for application development and commercialisation.
Collaborative projects with academic groups and grant‑funded programmes to develop, validate and translate diagnostics from concept to prototype.
Expertise Areas
- Point-of-care diagnostics
- Rapid bacterial detection and quantitation
- Phenotypic antibiotic susceptibility testing
- Assay and probe chemistry development
Key Technologies
- Latex agglutination assay
- Sugar‑based nanoprobe fluorescence detection
- Fluorescence emission quantitation
- Growth‑free phenotypic AST
News & Updates
Bristol, UK, November 5 2024. FluoretiQ announced the creation of a Commercial Advisory Board to assist with the launch of its VERI-5® product line, a 15-minute point-of-care test for urinary tract infections.
FluoretiQ announced the appointment of Mr Bill Pelling, former MD of bioMerieux, as Chair of its Board of Directors.
FluoretiQ announced a new initiative in its fight against AMR by securing an exclusive license to AST technology.
Bristol, UK, November 5 2024. FluoretiQ announced the creation of a Commercial Advisory Board to assist with the launch of its VERI-5® product line, a 15-minute point-of-care test for urinary tract infections.
FluoretiQ announced the appointment of Mr Bill Pelling, former MD of bioMerieux, as Chair of its Board of Directors.
FluoretiQ announced a new initiative in its fight against AMR by securing an exclusive license to AST technology.